English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/165834
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Dysregulated miRNAs and their pathogenic implications for the neurometabolic disease propionic acidemia

AuthorsRivera-Barahona, Ana ; Fulgencio-Covián, Alejandro; Pérez-Cerdá, Celia; Ramos, Ricardo; Barry, Michael A; Ugarte, Magdalena ; Pérez, Belén ; Richard, Eva ; Desviat, Lourdes R.
KeywordsSCE/dRING
dRYBP
Apoptosis
Drosophila
E3-ubiquitin ligases
Dp53 tumor suppressor
Polycomb
Issue Date18-Jul-2017
PublisherNature Publishing Group
CitationScientific Reports 7 (2017)
AbstractmiRNome expression profiling was performed in a mouse model of propionic acidemia (PA) and in patients' plasma samples to investigate the role of miRNAs in the pathophysiology of the disease and to identify novel biomarkers and therapeutic targets. PA is a potentially lethal neurometabolic disease with patients developing neurological deficits and cardiomyopathy in the long-Term, among other complications. In the PA mouse liver we identified 14 significantly dysregulated miRNAs. Three selected miRNAs, miR-34a-5p, miR-338-3p and miR-350, were found upregulated in brain and heart tissues. Predicted targets involved in apoptosis, stress-signaling and mitochondrial function, were inversely found down-regulated. Functional analysis with miRNA mimics in cellular models confirmed these findings. miRNA profiling in plasma samples from neonatal PA patients and age-matched control individuals identified a set of differentially expressed miRNAs, several were coincident with those identified in the PA mouse, among them miR-34a-5p and miR-338-3p. These two miRNAs were also found dysregulated in childhood and adult PA patients' cohorts. Taken together, the results reveal miRNA signatures in PA useful to identify potential biomarkers, to refine the understanding of the molecular mechanisms of this rare disease and, eventually, to improve the management of patients.
URIhttp://hdl.handle.net/10261/165834
Identifiersdoi: 10.1038/s41598-017-06420-8
issn: 2045-2322
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
DesviatLR_DysregulatedmiRNAsAndTheirPathogenic.pdf2,12 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.